AzTrials
AzTrials

Congenital Adrenal HyperplasiaNCT03897504

Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty

A study testing feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap in people with Congenital Adrenal Hyperplasia, run by Kasr El Aini Hospital at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Background and Rationale: The vaginoplasty remains a challenge for the surgeon. The most commonly used techniques have been: the Y-V plasty described by fortunoff for low vagina, the pullthrough operation described by Hendren and Crawford for high vagina, and the passerini-Glazer technique . Read more about this study

Who is it for?
Ages 18 months to 14 years, women only
Conditions the study is for
Congenital Adrenal Hyperplasia
What is being tested?
feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
5 participants
Where
1 siteEgypt
Study dates
1 Mar 2017to 1 Jan 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 months to 14 years
  • Women only
  • No healthy volunteers
  • Child

Who may be able to join

  • Females (46, XX genotype identified by karyotype
  • Age: infants and children from 18 months old age to 14 years
  • Virilized external genitalia.
  • Persistent urogenital sinus
  • Congenital adrenal hyperplasia.
  • Controlled by glucocorticoid and mineralocorticoid replacement therapy and clinically and hormonally judged fit for surgical interventions.
  • Voluntarily provided informed written consent of the parents for the planned procedure and possible risks.
  • Informed written approval of the parents of the included children to use clinical data collected in a research program.

Who cannot join

  • Male disorders of sexual development (46 XY)
  • Debatable sex of rearing; Mixed gonadal dysgenesis, Ovotesticular disorders of sexual development and partial androgen insensitivity syndrome.
  • Inadequate compliance with corticosteroid therapy, rendering surgery or interventions clinically hazardous or unsuitable.
  • Inadequately controlled hormonal assay: elevated androgens.
  • Patients who did any corrective surgery before.

Trial locations and contacts

1 site in 1 country.

Egypt1 site, 1 recruiting
  • faculty of medicine- Cairo University

    Cairo, El Manial, 12613

    Mahmoud T Mohammed, assistan lecturer, 01111830411 ext. 002, Mahmoud.tarek@kasralainy.edu.eg

    Ahmed K weshahi, lecturer, 01095227442 ext. 002, ahmed.kadry@kasralainy.edu.eg

    Recruiting

Other trials in Egypt

About this study

Official title: Surgical Evaluation Of Using The Inner Surface Of The Prepuce In Feminizing Genitoplasty In Cases Of Verilized Females With Congenital Adrenal Hyperplasia

Background and Rationale: The vaginoplasty remains a challenge for the surgeon. The most commonly used techniques have been: the Y-V plasty described by fortunoff for low vagina, the pullthrough operation described by Hendren and Crawford for high vagina, and the passerini-Glazer technique . None of these procedures is entirely satisfactory; with the first two, the neovagina has a tendency to become stenotic in most cases. Moreover, in the third, in addition to the high rate of stenosis, which is encountered in a third of case , the high rate of urethro-vaginal fistulas is unacceptable

Objectives :

Read more

To describe and evaluate a surgical technique for vaginoplasty that is easy to realize with fewer complications especially vaginal stenosis.

Study population \& Sample size : 24 patients suffering from congenital adrenal hyperplasia (CAH) presenting to outpatient clinic of diabetis Endocrine And Metabolism Pediatric Unit (DEMPU) of Cairo University Specialized Pediatric Hospital will be considered.

Study Design : non-controlled prospective clinical trial with all patients included in single group

Methods: Cystoscopy will be done promptly before proceeding to surgery, Confluence depth more than 20 mm is considered high anomaly, feminizing genitoplasty will be done as a one-stage procedure, One month after operation, examination under anesthesia will be done with calibration of vagina.

Possible Risk (s) to study population : The risk of this study is involving a vulnerable group of females which exposed to lengthy operation may complicate with bleeding and need for blood transfusion, infection early after surgery or vaginal stenosis.

Outcome parameter (s):

Vaginal calibration using hegars dilators Urodynamics for females older than 3 years and complaining from incontinence

Read the detailed description
  • Background and Rationale: Disorders of sex development(DSD) are medical conditions in which the development of chromosomal, gonadal, or anatomic sex varies from normal and may be incongruent with each other. Five main groups of DSD patients may be identified, submitted to the gender assignment process, and may be considered for a surgical genital reconstruction. (Lee Pa et al, 2006) Congenital adrenal hyperplasia (CAH) refers to a group of autosomal recessive disorders resulting from deficiency of one of the five enzymes required for synthesis of cortisol in the adrenal cortex. CAH is the most common cause of genital ambiguity. (van der Zwan, 2013) About 90-95% of individuals with CAH have a mutation in CYP21A2 gene, encoding 21-hydroxylase enzyme. The worldwide incidence of classical 21 OHD is 1:15,000 to 1:16,000 live births of which approximately 75% are salt wasters. That leads to a block of normal production of cortisone and results in overproduction of steroid metabolism by-products through pituitary feedback. These androgenic steroids lead to a variable degree of masculinization of normal female fetus.

The goal of therapy in CAH is to both correct the deficiency in cortisol secretion and suppresses adrenocorticotropic hormone (ACTH) overproduction. Proper treatment with glucocorticoid reduces stimulation of the androgen pathway, thus preventing further virilization and allowing normal growth and development. In addition to hormonal therapy, feminizing reconstructive surgery targets the correction of anatomical disturbance. The feminizing genitoplasty operation consists of reducing the size of the phallus (clitoroplasty), creating labia minora and vaginoplasty.

  • Sample size: Sample size calculation: n = 2(Za+Z1-β)2σ2/Δ2 n sample size Za = 1.65 ( p<0.05 as acceptable and a study with 80% power; using the below table, we get the following values: Zα, is 1.65 a error 5% 1% .1% 2 sided 1.96 2.5758 3.2905

1 sided 1.65 2.33 Z1-,β= 0.8416 power 80% 85% 90% 95% value 0.8416 1.0364 1.2816 1.6449 σ standard deviation =0 .5 Δ effect size 36% =0.36 Effect of using the prepuce in minimizing vaginal stenosis is 100% - effect of using other techniques 64%

N =2(1.65+0.8416)2 0.52 / 0.362 = 24 patients.

  • Study Design: non-controlled prospective clinical trial with all patients included in single group.
  • Ethical committee approval : approved (N-100-2018)
  • Study Methods

Population of study \& disease condition:

24 patients suffering from congenital adrenal hyperplasia (CAH) presenting with virilized external genitalia to outpatient clinic of diabetes Endocrine And Metabolism Pediatric Unit (DEMPU) of Cairo University Specialized Pediatric Hospital will be considered.

Methodology in details :

Patient recruitment females with congenital adrenal hyperplasia presenting with persistent urogenital sinus and virilized external genitalia to the outpatient clinic of Diabetes Endocrine And Metabolism Pediatric Unit (DEMPU) of Cairo University Specialized Pediatric Hospital

Pre-operative management History taking laying stress on age at diagnosis, family history of similar conditions and consanguinity in addition to any salt losing events.

Reviewing the patients charts for the investigations (basal adrenal precursors, karyotype, pelvic ultrasound) Complete genital examination to detect the degree of virilization (number and types of openings, the presence of rugae or pigmentation, phallus size and Prader scale).

Routine pre-operative blood tests will be done .

Perioperative hormonal therapy in the form of hydrocortisone and/or fludrocortisone in conjunction with pediatric anesthesia and pediatric endocrinology teams including dose adjustment and electrolytes follow up.

Genitography: Patient is generally anesthetized either in same setting of surgery or pre-operatively in different setting, The depth of confluence from perineal marker is measured in ratio to perineal marker dimensions whatever the scale of genitography picture is, then measurements are taken in millimeters. Other measurements of proximal urethra and vagina to the confluence are taken.

Operative technique Cystoscopy will be done promptly before proceeding to surgery in the same setting.

Confluence depth more than 20 mm is considered high anomaly with consequent difficult and lengthy procedure with high probability of need to use vaginal pullthrough in combination with the use of inner layer of the prepuce.

feminizing genitoplasty will be done as a one-stage procedure. The patient is placed in the lithotomy position for the best exposure of the perineum. A Foley catheter French 6 is placed in the vagina to facilitate identification of structures during dissection, The clitoroplasty will be attempted in all Cases.

The dissection of the flap from the inner surface of the prepuce with its pedicle will be done after measuring the distance between the native vagina and perineum. and then tubularized onto a rectal stent (French 12 or 14).

The proximal edge of the preputial flap will be sutured to upper vagina and its distal edge to outer edge. The rectal drain will be left in the vagina for 5 days postoperatively, by this technique the vaginoplasty can be achieved without further mobilization of the vagina which may affect the continence of the patient if we divide pubourethral ligament, labia this procedure will be followed by clitoroplasty and labioplasty.

In cases of low urogenital sinus (less than 2 cm), the use of preputial flap alone is often sufficient.

in case of high confluence additional procedure will be done in the form of laparoscopic vaginal pull-through

Postoperative management:

Wound will be closed by x-shaped bandage for 24 hours.

Vitamin K, ethamsylate (dicynone) and tranexamic acid (cyklokapron) will be given to help in hemostasis.

After dressing removal the wound will be left exposed and flushed with sterile -saline every 4-6 hours

Urinary catheter and vaginal stent will be removed on 5th to 7th day post operatively.

Parenteral broad spectrum antibiotics and antianaerobes will be given for one week. Stress doses of steroids will be continued for 2-3 days after surgery at double usual oral dose followed by tapering and returning to the original dose

postoperative management: One month after operation, examination under anaesthesia will be done with calibration of vagina using Hegar dilators and making decision for further need for repeated vaginal dilatation.

Urodynamics will be applied for patients older than 3 years old to asses the continence in cases with high confluence.

Primary outcome:

To calibrate the vagina and asses the degree of vaginal stenosis if present and need for further vaginal dilatation.

Secondary outcome:

To asses other outcomes specially the continence in patients older than 3 years old and the prescence of urethrovaginal fistula.

Short term complications:

  • Infection at vestibule and incision lines
  • accidental removal of the catheter
  • haematoma
  • secondary haemorrage

Intermediate and long term complications:

  • urethrovaginal fistula
  • recurrent persistant urogenital sinus (UGS)
  • Vaginal stenosis
  • Urinary incontinence
Being tested
feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap
Keywords
congenital adrenal hyperplasia, Feminizing genitoplasty, Vaginal stenosis
Medical subject headings
Adrenal Hyperplasia, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flapProcedure or surgery

    the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.

Study groups in NCT03897504
Study groupRoleWhat they receive
feminizing genitoplasty using inner surface of the prepuceExperimentalFeminizing genitoplasty will be done using the prepuce as a pedicled tubularized flap to create the new vagina, the new vagina which the investigators create it from the prepuce will be sutured above to the native vagina after its separation from the urogenital sinus, and the remaining part of the urogenital sinus will be used to create the urethra, the remaining part of the prepuce will create the labia minora, clitoroplasty will be attempted in all patients.
Receives: Procedure: feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. vaginal size calibration

    the new vagina will be assessed for stenosis 1 month after the procedure using Hegar dilators under general anaesthesia, further calibration will be done over 6 months to ensure patency of the vagina and to avoid stenosis by dilatation if stenosis encountered

    Measured: 6 months to one year

Secondary outcomes (1)
  1. urinary incontinence

    in patient older than 3 years and complaining from incontinence, urodynamics will be done.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2019
  2. Study start1 Mar 2017
  3. Primary completion1 Jan 2020 (estimated)
  4. Study completion1 Jan 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
5 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03897504
Sponsor's protocol ID
N-100-2018
Status last verified
Dec 2019
First submitted
28 Mar 2019
Last updated
2 Jan 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap in people with Congenital Adrenal Hyperplasia, run by Kasr El Aini Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 2 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

vaginal size calibration (time frame: 6 months to one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in